Biocon Limited
2,136words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
8, 2022 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National
23%
B I O C O N L I M I T E D B I O C O N L I M I T E D 8 8 8 Financial Highlights: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y
₹2,217
C O N L I M I T E D B I O C O N L I M I T E D 8 8 8 Financial Highlights: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Co
₹1,808
M I T E D B I O C O N L I M I T E D 8 8 8 Financial Highlights: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA*
29%
L I M I T E D 8 8 8 Financial Highlights: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % ma
19%
8 8 Financial Highlights: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA %
8%
s: Q1FY23 Revenue +23% ₹2,217Cr ₹1,808Cr Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr
25%
Biosimilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr 22% ₹530Cr 30% ₹437Cr 24% Profit Before
₹660
imilars +29% | Generics +19% | Research Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr 22% ₹530Cr 30% ₹437Cr 24% Profit Before Tax
31%
rch Services +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr 22% ₹530Cr 30% ₹437Cr 24% Profit Before Tax +19% ₹197Cr ₹166Cr % margin Net
9%
rvices +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr 22% ₹530Cr 30% ₹437Cr 24% Profit Before Tax +19% ₹197Cr ₹166Cr % margin Net Prof
₹478
es +8% Q 1 F Y 2 3 Q 1 F Y 2 2 Core EBITDA* +25% ₹660Cr % margin EBITDA % margin 31% +9% ₹478Cr 22% ₹530Cr 30% ₹437Cr 24% Profit Before Tax +19% ₹197Cr ₹166Cr % margin Net Profit %
Advertisement